{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:36:41Z","timestamp":1754109401827},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,1,21]],"date-time":"2008-01-21T00:00:00Z","timestamp":1200873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The large (<jats:italic>n<\/jats:italic>\u2003=\u200318\u2003325) Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) study demonstrated a significant gastrointestinal benefit with lumiracoxib 400\u2003mg o.d. (4\u00d7 the recommended dose in osteoarthritis) vs. naproxen 500\u2003mg b.d. or ibuprofen 800\u2003mg t.d.s.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To investigate how early a reduction in ulcer complications could be detected with lumiracoxib vs. nonselective nonsteroidal anti\u2010inflammatory drugs in TARGET.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Pointwise 95% confidence intervals were generated for the between\u2010treatment differences in Kaplan\u2013Meier estimates for definite or probable upper gastrointestinal ulcer complications (ulcer complications) and for all ulcers.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In patients not on aspirin, there was a significant reduction in all ulcers by day 8 and in ulcer complications by day 16 with lumiracoxib compared with both nonselective nonsteroidal anti\u2010inflammatory drugs combined, by day 6 (all ulcers) and day 14 (ulcer complications) vs. naproxen and by day 32 (all ulcers) and day 33 (ulcer complications) vs. ibuprofen.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Even with short\u2010term use, there are gastrointestinal safety benefits for lumiracoxib vs. nonselective nonsteroidal anti\u2010inflammatory drugs.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2008.03622.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T14:16:57Z","timestamp":1279894617000},"page":"838-845","source":"Crossref","is-referenced-by-count":8,"title":["Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti\u2010inflammatory drugs early after the initiation of treatment \u2013 findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial"],"prefix":"10.1111","volume":"27","author":[{"given":"C. J.","family":"HAWKEY","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. M.","family":"WEINSTEIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"STRICKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"MURPHY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"RICHARD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"KRAMMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"REBULI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00682-3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.suppl_1.7"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.11.1095"},{"issue":"4","key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase\u20102 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein JL","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2001.0510"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02118.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000282"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07598.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706078"},{"issue":"1","key":"e_1_2_6_12_2","first-page":"259","article-title":"The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX\u20102","volume":"61","author":"Marshall PJ","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.5.566"},{"issue":"1","key":"e_1_2_6_14_2","first-page":"A\u2010345","article-title":"Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients","volume":"122","author":"Hawkey CJ","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_6_15_2","first-page":"1804","article-title":"Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis","volume":"31","author":"Hawkey CC","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00318-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_6_20_2","first-page":"89","article-title":"Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non\u2010steroidal anti\u2010inflammatory drugs: what are the connections?","volume":"587","author":"McCarthy DM","year":"2002","journal-title":"Eur J Surg"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02026.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290816"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331101"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340502"},{"key":"e_1_2_6_25_2","author":"EMEA","journal-title":"European Medicines Agency Concludes Action on COX-2 Inhibitors"},{"key":"e_1_2_6_26_2","author":"FDA Memorandum","journal-title":"Analysis and Recommendations for Agency Action Regarding Non-steroidal Anti-inflammatory Drugs and Cardiovascular Risk"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-10-787"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-1-1"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03327372"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.015925"},{"key":"e_1_2_6_31_2","article-title":"Reduction of symptomatic ulcers with lumiracoxib compared with naproxen in patients over 65\u2003years old on low\u2010dose aspirin","volume":"65","author":"Hawkey CJ","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2008.03622.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2008.03622.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:58:04Z","timestamp":1697201884000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2008.03622.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,21]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1365-2036.2008.03622.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03622.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,21]]}}}